UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
6-K
Report
of Foreign Private Issuer
Pursuant
to Rule 13a-16 or 15d-16
under
the Securities Exchange Act of 1934
For
the month of: November 2025
Commission
file number: 001-41557
CLEARMIND
MEDICINE INC.
(Translation
of registrant’s name into English)
101
– 1220 West 6th Avenue
Vancouver,
British Columbia
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
CONTENTS
Attached
hereto and incorporated herein is the Registrant’s press release issued on November 18, 2025, titled “Clearmind Medicine
Announces Positive Top-Line Results from First Cohort of its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder”.
The
first three paragraphs of the press release attached to this Form 6-K as Exhibit 99.1 are incorporated by reference into the
Registrant’s Registration Statements on Form F-3 (File Nos. 333-275991, 333-270859, 333-273293)
and Form S-8 (File No. 333-283695),
filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the
extent not superseded by documents or reports subsequently filed or furnished.
EXHIBIT
INDEX
| Exhibit
No. |
|
|
| 99.1 |
|
Press release titled: “Clearmind Medicine Announces Positive Top-Line Results from First Cohort of its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder” |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
| |
Clearmind
Medicine, Inc. |
| |
(Registrant) |
| |
|
|
| Date:
November 18, 2025 |
By: |
/s/
Adi Zuloff-Shani |
| |
Name:
|
Adi
Zuloff-Shani |
| |
Title: |
Chief
Executive Officer |
3
